Cash, Cash Equivalents, and Short-term Investments in USD of DiaMedica Therapeutics Inc. from Q4 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.
Summary
DiaMedica Therapeutics Inc. quarterly Cash, Cash Equivalents, and Short-term Investments history and change rate from Q4 2019 to Q3 2025.
  • DiaMedica Therapeutics Inc. Cash, Cash Equivalents, and Short-term Investments for the quarter ending 30 Sep 2025 was $55,300,000, a 10% increase year-over-year.
Source SEC data
View on sec.gov
Cash, Cash Equivalents, and Short-term Investments, Quarterly (USD)
Cash, Cash Equivalents, and Short-term Investments, YoY Quarterly Change (%)

DiaMedica Therapeutics Inc. Quarterly Cash, Cash Equivalents, and Short-term Investments (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $55,300,000 +$5,100,000 +10% 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $30,000,000 -$24,100,000 -45% 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $37,300,000 -$9,200,000 -20% 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $44,100,000 -$8,800,000 -17% 31 Dec 2024 10-K 17 Mar 2025 2024 FY
Q3 2024 $50,200,000 -$6,000,000 -11% 30 Sep 2024 10-Q 13 Nov 2024 2024 Q3
Q2 2024 $54,100,000 -$6,600,000 -11% 30 Jun 2024 10-Q 07 Aug 2024 2024 Q2
Q1 2024 $46,500,000 +$17,800,000 +62% 31 Mar 2024 10-Q 08 May 2024 2024 Q1
Q4 2023 $52,900,000 +$19,400,000 +58% 31 Dec 2023 10-K 19 Mar 2024 2023 FY
Q3 2023 $56,200,000 +$20,100,000 +56% 30 Sep 2023 10-Q 13 Nov 2023 2023 Q3
Q2 2023 $60,700,000 +$22,300,000 +58% 30 Jun 2023 10-Q 14 Aug 2023 2023 Q2
Q1 2023 $28,700,000 31 Mar 2023 10-Q 15 May 2023 2023 Q1
Q4 2022 $33,500,000 31 Dec 2022 10-K 28 Mar 2023 2022 FY
Q3 2022 $36,100,000 +$19,900,000 +123% 30 Sep 2022 10-Q 09 Nov 2022 2022 Q3
Q2 2022 $38,400,000 +$36,200,000 +1645% 30 Jun 2022 10-Q 11 Aug 2022 2022 Q2
Q3 2021 $16,200,000 +$6,400,000 +65% 30 Sep 2021 10-Q 10 Nov 2021 2021 Q3
Q2 2021 $2,200,000 -$2,800,000 -56% 30 Jun 2021 10-Q 11 Aug 2021 2021 Q2
Q1 2021 $3,300,000 $0 0% 31 Mar 2021 10-Q 05 May 2021 2021 Q1
Q3 2020 $9,800,000 30 Sep 2020 10-Q 04 Nov 2020 2020 Q3
Q2 2020 $5,000,000 30 Jun 2020 10-Q 11 Aug 2020 2020 Q2
Q1 2020 $3,300,000 31 Mar 2020 10-Q 13 May 2020 2020 Q1
Q4 2019 $7,900,000 31 Dec 2019 10-K 23 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.